This website uses cookies
Read our Privacy policy and Terms of use for more information.
Long Form Content
Aug 14, 2025
•
8 min read
🧬 Sarepta touts new DMD safety data (no ambulatory deaths), Vor's Sjögren's syndrome disease bet hits late stage trial success in China, Hatteras Venture Partners news $200M biotech/healthtech fund, HopeAI's partners with Mayo Clinical on AI-powered trial design, Treg takes an L as Abata Tx shutters, Generation Bio cuts 90% of staff
Aug 13, 2025
🧬 Summit skips quarterly call as AstraZeneca deal rumors fly, Bayer + Kumquat Biosciences' up to $1.3B KRAS G12D inhibitor deal, Eli Lilly + UK gov launch obesity care access initiative, Insmed scores FDA approval for bronchiectasis therapy, FDA may deny renewed authorization for Pfizer's pediatric COVID vaccine
Aug 12, 2025
🧬 Another Chinese biotech licensing deal (Expedition Therapeutics & Fosun Pharma), NextRNA closes shop, 10x Genomics to acquire Scale Biosciences, and BridgeBio Oncology Therapeutics completes SPAC integration
Aug 11, 2025
9 min read
🧬 Prasad's back at CBER, Strand raises $153M, FDA restricts bluebird bio's Skysona gene therapy
Aug 10, 2025
22 min read
🧬 A one-off TLDR Biotech update covering last week
Aug 4, 2025
7 min read
🧬 Sanofi buys China rights to Arrowhead's rare metabolic disease therapy, 4DMT rises on positive Ph2 DME gene therapy data, new Cayman Island-based biotech buys rights to two pre-clinical TCE assets from China's Lepu Biopharma
Aug 1, 2025
10 min read
🧬 AbbVie's $1B psychedelics play, Novo Nordisk's hemophilia antibody Alhemo lands FDA approval, Trump goes after big pharma with most-favored nations threats
Jul 31, 2025
🧬 GSK's committed to US investment ("tens of billions" in fact), Teva not bothered by tariffs, and Biogen, Eisai present positive long-term Leqembi data in Alzheimer's disease
Jul 30, 2025
🧬 FDA's big CBER shake-up, Novo Nordisk dives while AstraZeneca soars, and massive cuts coming to Merck & Co. ($3B by EOY 2027)
Jul 29, 2025
11 min read
🧬 MapLight's $372.5M Series D, Adaptimmune sells-out (commercial assets)
Jul 28, 2025
🧬 Hengrui & GSK link-up on 12 medicines, while Roche still in it for the gene therapy long-game
Jul 25, 2025
🧬 3-peat of CGT layoffs, Eli Lilly goes in on molecular gates (up to $856M), and FDA (likely) wants new safety studies for Sarepta's Elevidys
